LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Search

Glaukos Corp

Suletud

SektorTervishoid

107.44 -3.94

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

107.44

Max

108.73

Põhinäitajad

By Trading Economics

Sissetulek

-117M

-134M

Müük

9.6M

143M

Aktsiakasum

-0.16

Kasumimarginaal

-93.387

Töötajad

1,094

EBITDA

-129M

-130M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+23.87% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

29. apr 2026

Turustatistika

By TradingEconomics

Turukapital

747M

7B

Eelmine avamishind

111.38

Eelmine sulgemishind

107.44

Uudiste sentiment

By Acuity

35%

65%

70 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Glaukos Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

28. jaan 2026, 18:25 UTC

Suurimad hinnamuutused turgudel

Glaukos Shares Rise After FDA Approves NDA Supplement for iDose TR

Võrdlus sarnastega

Hinnamuutus

Glaukos Corp Prognoos

Hinnasiht

By TipRanks

23.87% tõus

12 kuu keskmine prognoos

Keskmine 133.45 USD  23.87%

Kõrge 165 USD

Madal 72 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Glaukos Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

13

Osta

0

Hoia

1

Müü

Tehniline skoor

By Trading Central

87.61 / 93Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

70 / 351 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat